Acta Neuropathologica Communications

Acta Neuropathologica Communications is an international peer-reviewed open access journal founded in 2013 and published by BioMed Central, part of Springer Nature, as the sister journal of Acta Neuropathologica, devoted to the pathology and mechanisms of neurological disease, with a 2025 Journal Impact Factor of 6.5《神经病理学通讯》（Acta Neuropathologica Communications）创刊于 2013 年，是施普林格·自然旗下（BioMed Central）出版的国际同行评审开放获取期刊，为（Acta Neuropathologica）的姊妹刊，致力于神经系统疾病的病理学与机制研究，2025 年影响因子为 6.5。

Scope

• According to its official aims, the journal publishes articles on the mechanisms of neurological disease based on experimental or human tissues using molecular, cellular and morphological techniques按其官方宗旨，该刊发表基于实验或人体组织、采用分子、细胞与形态学技术研究神经系统疾病机制的论文。
• Its scope covers experimental and descriptive articles on the pathology of disorders of the nervous system and skeletal muscle, using morphological, molecular and cell biology methods其范围涵盖采用形态学、分子与细胞生物学方法研究神经系统与骨骼肌疾病病理学的实验性与描述性论文。
• Observational work on human and animal tissues is welcome alongside experimental studies in in vivo and in vitro models of neurological disease该刊既欢迎基于人与动物组织的观察性研究，也欢迎采用体内与体外神经系统疾病模型的实验研究。
• Studies that bridge neuropathology with biomarker analysis, neuroimaging or neurophysiology fall squarely within its interests把神经病理学与生物标志物分析、神经影像或神经生理学相结合的研究正属其兴趣范围。
• Published research spans neurodegenerative conditions such as Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis and Tau proteinopathies, brain tumours, neuroinflammation and demyelinating disease, neuromuscular disorders, epilepsy and infectious or traumatic injury of the nervous system已发表研究覆盖阿尔茨海默病、帕金森病、肌萎缩侧索硬化与 Tau 蛋白病等神经退行性疾病，以及脑肿瘤、神经炎症与脱髓鞘疾病、神经肌肉病、癫痫和神经系统感染或创伤。
• Accepted article types include original research, reviews, case reports, letters to the editor and commentaries该刊接收原创研究、综述、病例报告、致编辑函与评论等文章类型。
• As part of the Springer Nature portfolio, the journal receives transfers through the Springer Nature Transfer Desk, and manuscripts originally reviewed for its sister journal Acta Neuropathologica may be moved to it at the authors request作为施普林格·自然集团旗下期刊，该刊通过（Transfer Desk）接收转投稿件，经（Acta Neuropathologica）评审过的稿件也可应作者要求转入本刊。

History

• The journal was launched on 8 May 2013, when BioMed Central published volume 1 as a fully open access companion to the Springer journal Acta Neuropathologica, with Werner Paulus of the University Hospital Münster in Germany as founding editor-in-chief该刊于 2013 年 5 月 8 日创刊，（BioMed Central）以完全开放获取形式推出第 1 卷，作为施普林格旗下（Acta Neuropathologica）的伴生刊，德国明斯特大学医院的（Werner Paulus）任创刊主编。^[1]
• The founding editorial set house rules that still define the journal: only minor revisions, to be performed within three weeks, a mean of about 11 days from submission to first decision, and no more than two months from submission to online publication创刊社论确立了沿用至今的办刊规则：只要求可在三周内完成的小修，投稿至首次决定平均约 11 天，投稿至在线发表不超过两个月。
• Johannes Attems of Newcastle University served as co-editor-in-chief from 2014 to 2018, Paulus retired in 2018, and Jeroen Hoozemans of Amsterdam University Medical Centers led the journal until his retirement in 2024纽卡斯尔大学的（Johannes Attems）于 2014 至 2018 年任共同主编，保卢斯（Paulus）于 2018 年退休，阿姆斯特丹大学医学中心的（Jeroen Hoozemans）执掌该刊至 2024 年退休。
• The open access model has been complete since launch: a single article processing charge regardless of length, no page charges for an online-only journal, unlimited figures, and author-retained copyright under CC BY or CC BY-NC-ND licences自创刊起即实行完全开放获取模式：按篇收取单一文章处理费，纯在线刊不收版面费，图片数量不限，作者在（CC BY）或（CC BY-NC-ND）许可下保留版权。
• The journal was indexed for MEDLINE, PubMed Central and Scopus from volume 1 in 2013 and is also covered by the Science Citation Index Expanded, with downloads reaching 2.8 million in 2025该刊自 2013 年第 1 卷起被（MEDLINE）、（PubMed Central）与（Scopus）收录，亦被科学引文索引扩展版收录，2025 年下载量达 280 万次。
• Its impact factor was 7.801 in 2021 and 7.578 in 2022, settled at 5.7 in 2024 with a five-year factor of 6.6, and stood at 6.5 in 2025, placing it 45th of 330 journals in the Neurosciences category, with a median of 9 days from submission to first decision其影响因子 2021 年为 7.801、2022 年为 7.578，2024 年为 5.7（五年期影响因子 6.6），2025 年为 6.5，在神经科学类 330 种期刊中列第 45 位，投稿至首次决定的中位时间为 9 天。

Editors

• The current editors-in-chief are Panteleimon Giannakopoulos of the University of Geneva in Switzerland and Jason T. Huse of the University of Texas MD Anderson Cancer Center in the United States, who took over after Hoozemans retired in 2024现任共同主编为瑞士日内瓦大学的（Panteleimon Giannakopoulos）与美国得克萨斯大学（MD Anderson）癌症中心的（Jason T. Huse），二人在（Hoozemans）2024 年退休后接任。
• The founding editor Werner Paulus of the University of Münster retired in 2018, and former editors-in-chief Johannes Attems and Jeroen Hoozemans retired in 2019 and 2024 respectively明斯特大学的创刊编辑（Werner Paulus）于 2018 年退休，前共同主编（Johannes Attems）与前主编（Jeroen Hoozemans）分别于 2019 年与 2024 年退休。
• The editorial group, initially about 30 colleagues recruited from the referee pool of Acta Neuropathologica, now spans Europe, North America, Asia and Australia, including scholars from Sapienza University of Rome, KU Leuven, Memorial Sloan Kettering Cancer Center, the Medical University of Vienna, the University of Southampton, Inserm, the University of North Carolina, the Icahn School of Medicine at Mount Sinai, the University of Helsinki, the University of Exeter, the University of Bern, the University of Pittsburgh, Amsterdam University Medical Centers, McMaster University and Yokohama City University编辑团队最初为约 30 位自（Acta Neuropathologica）审稿人群中遴选的同行，如今覆盖欧洲、北美、亚洲与澳大利亚，包括罗马第一大学、鲁汶大学、纪念斯隆-凯特琳癌症中心、维也纳医科大学、南安普顿大学、（Inserm）、北卡罗来纳大学、西奈山伊坎医学院、赫尔辛基大学、埃克塞特大学、伯尔尼大学、匹兹堡大学、阿姆斯特丹大学医学中心、麦克马斯特大学与横滨市立大学的学者。
• The journal operates a single-anonymized peer review system in which reviewers see the names of the authors while authors never learn the identity of the reviewers, and two or more experts typically assess each manuscript before the responsible editor takes the decision该刊实行单向匿名评审，审稿人可见作者姓名而作者无从知晓审稿人身份，每篇稿件通常由至少两位专家评审后由责任编辑作出决定。
• Article processing charges can be reduced or waived for authors in low-income countries, and discretionary waivers are considered case by case when requested at the point of submission低收入国家作者可减免文章处理费，其他作者在投稿时提出申请亦可个案酌免。
• The journal maintains close ties with its sister journal Acta Neuropathologica, running themed collections such as the EUROTAU series on Tau protein pathology and transferring suitable manuscripts between the two titles该刊与姊妹刊（Acta Neuropathologica）联系紧密，运行（EUROTAU）等 Tau 蛋白病理主题专辑，并在两刊之间转投合适稿件。